GENE ONLINE|News &
Global Diabetes Drug Market 2025: Top 10 Players and Industry Outlook
On November 6, 2025, President Trump announced agreements with Eli Lilly and Novo Nordisk to deliver “Affordable Weight-Loss Drugs for All.” Image: 123rf
Diabetes remains one of the world’s most pressing public health challenges. Aging populations, urban lifestyles, and shifting diets continue to drive prevalence in both Western and Asia-Pacific regions. In 2025, the global diabetes drug market reached a new record high, fueled by innovations in AI-driven healthcare and digital therapeutics. This report reviews the top 10 leading companies, regional dynamics, and emerging opportunities for the pharmaceutical sector.
Global Market Overview
According to Spherical Insights & Consulting, the global diabetes drug market surpassed USD 80 billion in 2025, growing at a steady CAGR of 6.66%. North America remains the largest market, while Europe shows the fastest growth. Key drivers include population aging, obesity, sedentary lifestyles, and public health initiatives promoting early diagnosis and treatment.
On the product front, GLP-1 receptor agonists and SGLT2 inhibitors dominate the market. Long-acting insulins and new oral therapies are also expanding rapidly. Digital health tools and continuous glucose monitoring further enhance patient self-management and clinical outcomes.
Top 10 Global Companies in the Diabetes Drug Market (2025)
GLP-1 Market Leaders:
Novo Nordisk (Denmark)
Novo Nordisk maintained leadership in 2025 with Ozempic® (semaglutide) and Rybelsus® (oral semaglutide). The company continued to dominate both GLP-1 and insulin therapy segments. However, its growth outlook faced pressure from strong competition with Eli Lilly.
Eli Lilly and Company (US)
Eli Lilly gained momentum with Mounjaro® (tirzepatide), a dual GLP-1/GIP receptor agonist. Its expanding portfolio across diabetes and obesity markets fueled rapid growth. Despite this, the company faced supply-chain and pricing challenges. Its CEO noted that while new US manufacturing plants are in progress, many key ingredients still rely on suppliers in China.
SGLT2 Market Leaders:
AstraZeneca (UK)
AstraZeneca’s Farxiga® (dapagliflozin) remained one of the fastest-growing SGLT2 inhibitors in 2025. Its proven benefits in cardio-renal-metabolic diseases strengthened its market position.
Boehringer Ingelheim (Germany)
Through its partnership with Lilly, Boehringer Ingelheim’s Jardiance® (empagliflozin) retained the largest market share among SGLT2 inhibitors. The company effectively expanded into cardiovascular and kidney-related indications beyond diabetes.
Other Major Players:
Sanofi (France)
Sanofi, known for Lantus® and Toujeo®, remains a historical leader in insulin therapy. However, with the global shift toward GLP-1 and SGLT2 drugs, its innovation pipeline in 2025 appeared less defined, signaling a strategic transition phase.
Novartis (Switzerland)
Although not a traditional diabetes giant, Novartis increasingly targets cardiovascular, renal, and metabolic diseases—positioning itself as a key player in managing diabetes-related comorbidities.
Johnson & Johnson (US)
Through Janssen, J&J previously led the SGLT2 segment with Invokana®. By 2025, its market share declined sharply, prompting a pivot toward integrated medical devices and drug technologies.
Takeda Pharmaceutical (Japan)
Takeda’s Nesina® (alogliptin) represents its main diabetes product. Yet the DPP-4 class has been heavily displaced by GLP-1 and SGLT2 drugs. Nesina® also lost key patent protection in 2025, exposing it to generic competition.
Merck & Co., Inc. (US)
Merck’s Steglatro®, developed with Pfizer, captured only a small share of the SGLT2 market. Its strategy focused on non-insulin regimens and prevention of diabetic complications.
Pfizer Inc. (US)
Pfizer’s presence in the diabetes market remained modest in 2025. However, its USD 10 billion acquisition of Metsera in November 2025 signaled renewed ambition. The deal included MET-097i (a once-monthly GLP-1 injection) and MET-233i (an amylin analog), strengthening Pfizer’s entry into next-generation metabolic therapeutics.
Asia-Pacific Diabetes drug market Insights (2025)
The Asia-Pacific diabetes drug market reached USD 25.7 billion in 2025, with a CAGR of 2.8%. While smaller than North America, its vast population and rising prevalence make it a critical growth region.
- China: Oral antidiabetic drugs dominate, supported by stable, high patient volume.
- Taiwan: Though smaller in size, Taiwan’s mature healthcare and strong IT infrastructure foster cross-sector innovation.
- Southeast Asia: Markets such as Thailand and Singapore are advancing regulatory reforms and digital health integration, driving regional growth.
Patent Expirations and Policy Risks Ahead
In the US—the world’s largest diabetes drug market—political forces have entered the pricing arena. On November 6, 2025, President Trump announced agreements with Eli Lilly and Novo Nordisk to deliver “Affordable Weight-Loss Drugs for All.”
Under the plan, upcoming oral GLP-1 drugs are expected to launch at USD 150 per month, while Medicare and Medicaid copays for injectable GLP-1s will drop to USD 50 per month. This initiative extends the administration’s Most-Favored-Nation Pricing policy, aiming to close the gap between US and international drug prices.
While this may broaden access to GLP-1 drugs for obesity and diabetes, it poses significant margin pressure for originator companies.
Meanwhile, semaglutide patents will start expiring in major countries—including India, China, Canada, and Brazil—from 2026 onward. These markets represent over 40% of the global population and a large share of obesity-related diseases. Though generics are expected to emerge, regulatory hurdles and manufacturing complexities may delay their actual entry.
Related posts:
Hims & Hers Health Inc. Tipping the Scales of the Weight Loss Market — and Wall Street is Loving it!
Can New GLP-1 Contenders Disrupt the Weight-Loss Giants, Lilly and Novo, in the Battle for Market Dominance?
Novo Nordisk Cracks Down on Unsafe Compounded “Semaglutide” with New Wave of Lawsuits
2024 Top 10 Diabetes Drugs and Promising Type 1 Treatments to Watch
LATEST
Study Finds Acute Pancreatitis Worsens Outcomes for Pediatric Stem Cell Transplant Patients
2026-01-16
Study Explores Patient Perspectives on Frailty Screening Implementation in Emergency Departments
2026-01-16
Researchers Identify SMPDL3B as Potential Biomarker and Therapeutic Target for Myalgic Encephalomyelitis
2026-01-16
Study Explores Transcriptomic Changes in Cryopreserved Human Ovarian Tissue Using 3D Culture Techniques
2026-01-16
